BRCA1 and BRCA2 gene mutations increase the risk of hereditary breast cancer. Here's what you should know about the causes, ...
Altamira’s polyKRASmut siRNA shown to knock down at least 65-91% of KRAS mutations in colorectal, non-small cell lung, and pancreatic cancer cell lines Fresh experimental data expected to strengthen ...
The Supreme Court has ruled that an unchallenged will is enough for land mutation. A landowner's registered will allows a ...
Altamira’s ability to target different KRAS mutations with a single polyvalent siRNA sequence illustrates versatility and potential of RNA therapeutics compared with conventional small molecule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results